259 LIBERTY AVENUE, STATEN ISLAND, NY
Acurx Announces Ibezapolstat Trial for Recurrent CDI Treatment
News, Articles of Incorporation
Shareholder votes
Announces Reverse Stock Split
Announces Exercise of Warrants for $2.67 Million Gross Proceeds
Annual Report to Security Holders
Reports First Quarter Results and Provides Business Update
FY 2025
Q3
Q2
Q1
FY 2024
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
S-1
Amended Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Submission Upload
Correspondence
Post-Effective Amendment to Registration Statement